Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance
ABCG2 is an efflux transporter conferring multidrug resistance (MDR) on cancer cells. However, the initial molecular events leading to its up-regulation in MDR tumor cells are poorly understood. Herein, we explored the impact of drug treatment on the methylation status of the ABCG2 promoter and cons...
Main Authors: | Eran E. Bram, Michal Stark, Shachar Raz, Yehuda G. Assaraf |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2009-12-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S147655860980105X |
Similar Items
-
GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs
by: Ze-Zhong Yu, et al.
Published: (2023-11-01) -
Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
by: Chung-Pu Wu, et al.
Published: (2020-01-01) -
The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs
by: Chung-Pu Wu, et al.
Published: (2022-05-01) -
CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
by: Lejia Xu, et al.
Published: (2023-12-01) -
Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells
by: Yan-Qing Li, et al.
Published: (2022-10-01)